首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1485篇
  免费   174篇
  国内免费   50篇
耳鼻咽喉   9篇
儿科学   98篇
妇产科学   19篇
基础医学   103篇
口腔科学   43篇
临床医学   115篇
内科学   548篇
皮肤病学   29篇
神经病学   29篇
特种医学   198篇
外科学   190篇
综合类   107篇
预防医学   74篇
眼科学   8篇
药学   64篇
中国医学   4篇
肿瘤学   71篇
  2023年   15篇
  2022年   8篇
  2021年   27篇
  2020年   21篇
  2019年   11篇
  2018年   34篇
  2017年   49篇
  2016年   41篇
  2015年   35篇
  2014年   67篇
  2013年   85篇
  2012年   36篇
  2011年   31篇
  2010年   66篇
  2009年   74篇
  2008年   41篇
  2007年   96篇
  2006年   37篇
  2005年   37篇
  2004年   35篇
  2003年   20篇
  2002年   24篇
  2001年   34篇
  2000年   23篇
  1999年   27篇
  1998年   81篇
  1997年   67篇
  1996年   65篇
  1995年   53篇
  1994年   48篇
  1993年   43篇
  1992年   24篇
  1991年   19篇
  1990年   27篇
  1989年   33篇
  1988年   35篇
  1987年   19篇
  1986年   33篇
  1985年   27篇
  1984年   17篇
  1983年   23篇
  1982年   20篇
  1981年   15篇
  1980年   12篇
  1979年   12篇
  1978年   11篇
  1977年   10篇
  1976年   14篇
  1975年   12篇
  1970年   4篇
排序方式: 共有1709条查询结果,搜索用时 31 毫秒
71.
72.
73.
74.
75.
Ancylostoma tubaeforme was originally described as a separate species parasitizing the cat. The adults of A. tubaeforme are 7 to 12 mm long. A. tubaeforme can be differentiated from the adults of A. braziliense and A. ceylanicum by the presence of three teeth. Here we describe the first report of A. tubaeforme in a Persian young female leopard, 2–3 years old, with head and trunk length 120 centimeters, length of tail 98 centimeters and body weight 35 kilograms.  相似文献   
76.
77.
78.
79.
Seiki Kiriyama  Kazuto Kozaka  Tadahiro Takada  Steven M. Strasberg  Henry A. Pitt  Toshifumi Gabata  Jiro Hata  Kui‐Hin Liau  Fumihiko Miura  Akihiko Horiguchi  Keng‐Hao Liu  Cheng‐Hsi Su  Keita Wada  Palepu Jagannath  Takao Itoi  Dirk J. Gouma  Yasuhisa Mori  Shuntaro Mukai  Mariano Eduardo Giménez  Wayne Shih‐Wei Huang  Myung‐Hwan Kim  Kohji Okamoto  Giulio Belli  Christos Dervenis  Angus C. W. Chan  Wan Yee Lau  Itaru Endo  Harumi Gomi  Masahiro Yoshida  Toshihiko Mayumi  Todd H. Baron  Eduardo de Santibañes  Anthony Yuen Bun Teoh  Tsann‐Long Hwang  Chen‐Guo Ker  Miin‐Fu Chen  Ho‐Seong Han  Yoo‐Seok Yoon  In‐Seok Choi  Dong‐Sup Yoon  Ryota Higuchi  Seigo Kitano  Masafumi Inomata  Daniel J. Deziel  Eduard Jonas  Koichi Hirata  Yoshinobu Sumiyama  Kazuo Inui  Masakazu Yamamoto 《Journal of hepato-biliary-pancreatic sciences》2018,25(1):17-30
Although the diagnostic and severity grading criteria on the 2013 Tokyo Guidelines (TG13) are used worldwide as the primary standard for management of acute cholangitis (AC), they need to be validated through implementation and assessment in actual clinical practice. Here, we conduct a systematic review of the literature to validate the TG13 diagnostic and severity grading criteria for AC and propose TG18 criteria. While there is little evidence evaluating the TG13 criteria, they were validated through a large‐scale case series study in Japan and Taiwan. Analyzing big data from this study confirmed that the diagnostic rate of AC based on the TG13 diagnostic criteria was higher than that based on the TG07 criteria, and that 30‐day mortality in patients with a higher severity based on the TG13 severity grading criteria was significantly higher. Furthermore, a comparison of patients treated with early or urgent biliary drainage versus patients not treated this way showed no difference in 30‐day mortality among patients with Grade I or Grade III AC, but significantly lower 30‐day mortality in patients with Grade II AC who were treated with early or urgent biliary drainage. This suggests that the TG13 severity grading criteria can be used to identify Grade II patients whose prognoses may be improved through biliary drainage. The TG13 severity grading criteria may therefore be useful as an indicator for biliary drainage as well as a predictive factor when assessing the patient's prognosis. The TG13 diagnostic and severity grading criteria for AC can provide results quickly, are minimally invasive for the patients, and are inexpensive. We recommend that the TG13 criteria be adopted in the TG18 guidelines and used as standard practice in the clinical setting. Free full articles and mobile app of TG18 are available at: http://www.jshbps.jp/modules/en/index.php?content_id=47 . Related clinical questions and references are also included.  相似文献   
80.

Aims

The management of patients with in‐stent restenosis (ISR) is still a major clinical challenge even in the era of drug‐eluting stents (DES). Recent studies have demonstrated acceptable clinical outcomes for the everolimus‐eluting bioresorbable vascular scaffold (BVS) ABSORB? in patients with stable coronary artery disease but data are scarce on its use in patients with ISR. We report the long‐term results of our preliminary experience with this novel approach at our institution.

Methods and Results

We investigated the safety and efficacy of BVS implantation to treat ISR. 34 consecutive patients (37 lesions) underwent PCI for ISR with BVS implantation between May 2013 and June 2015 at our institution and were included in the current analysis. Follow‐up was available in 91.9% of the patients. Mean follow‐up period was 801.9 ± 179 days. One patient had definite scaffold thrombosis (ScT) 2 months after stent implantation which was treated with DES. Five patients (six lesions) experienced target lesion revascularization (TLR). The composite endpoint rate of TLR, ScT, myocardial infarction, and death occured in 6/37 lesions at follow‐up (16.2%).

Conclusions

These real‐world data using BVS in patients with ISR demonstrates that ISR treatment with ABSORB? BVS is feasible but could have slightly higher target lesion failure rates as compared to DES. This proof of concept could be hypothesis‐generating for larger randomized controlled studies.
  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号